share_log

HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $10

Benzinga Real-time News ·  Jan 26, 2023 06:15

HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals (NASDAQ:ARDS) with a Buy and lowers the price target from $19 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment